Background {#Sec1}
==========

Trigeminal neuralgia (TN) is a chronic disorder characterized by paroxysms of unilateral, electric shock-like pain in the distribution of one or more branches of the trigeminal nerve \[[@CR1]\].Table 1Visit schedule and methodsFirst part: single blindSecond part: double blind, randomizedVisit schedule and methodsV-1 (Screening, 8 days before V0)V0 = open-label *verum* injectionV1 (28 ± 3 days after V0)V2 = randomized, doubleblind intervention (84 ± 3 days after V0)V3 (28 ± 2 days after V2)V4 (84 ± 3 days after V2)Patient's consentXInclusion/Exclusion criteriaXStandardized, semi-structured patient historyXXXXXXSF-12 Questionnaire assessing life qualityXXXXXXADS Questionnaire assessing depressionXXXXXXHIT-6 Questionnaire assessing pain severityXXXXXXNeurological examinationXXXXXMedical examinationXXXXXBlood testsXPain-evoked potentialsXXXXXRandomizationXBT-A/Placebo injectionX (*verum*)X (*verum*/placebo)Assessment of baseline TN frequencyXAssessment of therapy responseXXAssessment of adverse eventsXXXXXPseudonymizationPatients are assigned to a screening numberScreening numbers are assigned to randomization list*ADS* Allgemeine Depressionsskala: General Depression Scale, *HIT-6* Headache Impact Test-6, *SF-12* 12-item short form questionnaire, *TN* trigeminal neuralgia

It is estimated that approximately 4--28.9/100,000 people worldwide suffer from TN. It affects mainly the older population and is more common amongst women \[[@CR2], [@CR3]\]. The underlying cause of classic TN, as defined by the ICHD-3 beta (International Classification of Headache Disorders, third edition), is assumed to be neurovascular compression caused by cerebral vessels. In particular the superior cerebellar artery can locally affect the trigeminal nerve causing segmental demyelination and consecutively ephtatic conduction of painful paroxysms \[[@CR3]\].

Secondary forms caused by tumor, trauma, multiple sclerosis or post-herpetic neuralgia exist and are classified by the ICHD-3 beta as secondary painful trigeminopathies.

Single pain episodes of TN only last for a few seconds. The therapeutic strategy is prophylactic treatment. Treatment consists of anticonvulsive drugs such as carbamazepine (CBZ), oxcarbarzepine (OXC), phenytoin or gabapentin. Major treatment limitations are lack of efficacy and, in an older-aged population, intolerability due to central nervous system side effects. Drug refractory courses affect many patients \[[@CR4]\].

Evidence for the efficacy of interventional procedures such as gamma-knife surgery, microvascular decompression and percutaneous Gasserian ganglion intervention is limited and sensory side effects in the affected trigeminal branches are common \[[@CR5]\].

Botulinum neurotoxin type A (BT-A) is a potent neurotoxin derived from *Clostridium botulinum*. It blocks the release of acetylcholine at the neuromuscular junction and has also been found to inhibit the release of proinflammatory peptides. In addition BT-A binds to C- fibers. Analgesic efficacy is proven in the treatment of chronic migraine and its antinociceptive effects on neuropathic pain have been established in animal models \[[@CR6]\].

Subcutaneous injections of BT-A are a non-invasive treatment option, which is suitable for patients where drug therapy or neurosurgical intervention have failed. Its clinical effects on TN have been studied in several open and one double blind trial \[[@CR7]--[@CR12]\].

This trial will be conducted in a tertiary outpatient clinic specialized in the treatment of headache and facial pain.

Standard medical treatment {#Sec2}
--------------------------

First-line treatment agents in the therapy of TN are CBZ and OXC \[[@CR13], [@CR14]\].

CBZ has proven its efficacy in four randomized controlled trials (RCTs) and is approved for TN \[[@CR15]--[@CR18]\]. It is estimated that only 50 % of the patients remain long-term responders. Therapy-limiting side effects are common. In doses higher than 600 mg/d central nervous system side effects such as ataxia, fatigue and vertigo are very common. Auto- induction of metabolic liver enzymes can lower plasma CBZ levels and lead to numerous drug interactions.

In terms of efficacy oxcarbazepine is assumed to be comparable to CBZ but with a more favorable risk profile. Due to the lack of sufficient clinical data the evidence for its efficacy is limited and it can only be prescribed off-label. Under therapy, regular screening for hyponatremia is necessary \[[@CR19], [@CR20]\].

Second-line agents are the GABA-B-receptor-agonist baclofen and other anticonvulsive drugs such as phenytoin, gabapentin, lamotrigine, levetiracetam, pregabalin, topiramate, valproic acid with either insufficient clinical data or a less favorable risk profile \[[@CR21]--[@CR32]\].

All the aforementioned substances and combinations of substances can be taken for the duration of the clinical trial as long as the dosage remains unchanged.

Neurosurgical procedures {#Sec3}
------------------------

Neurosurgical procedures are considered alternative treatment options for patients with drug refractory courses:Microvascular decompression (Janetta procedure) is estimated to have a response rate of 68 % after ten years and is preferred over neuroablative procedures because trigeminal function will be preserved \[[@CR33]\]Percutaneous ablative procedures such as thermoablation of the Gasserian ganglion is estimated to have a 5-year response rate of 50 % and moderate to severe sensory side effects such as trigeminal hypoesthesia, or anesthesia dolorosa \[[@CR34]--[@CR36]\]Radiosurgical treatment with a gamma-knife has a lower response rate (41--45 % after 5 years) with a more favorable risk profile (sensory impairment in 7.7--49 %) \[[@CR37]\]

Previous studies of BT-A in trigeminal neuralgia {#Sec4}
------------------------------------------------

The efficacy of BT-A in classical TN has been investigated in several open-label studies and one RCT \[[@CR7]--[@CR12]\]. There were considerable variations in dosage (6--100 U BT-A per intervention) and the number/localization of injection sites (between 2 and 15).

Wu et al. conducted the sole RCT \[[@CR7]\]: 42 patients were allocated to either intradermal and optionally, if the second trigeminal branch was affected, submucosal injection of 75 U BT-A at 15 injection points in the area where the patient experienced pain. A response rate of 68 %, defined as \> 50 % visual analogue scale (VAS) score reduction (as compared to 15 % in the placebo group) has been reported after 12 weeks.

Hu et al. reviewed the previous studies and rated the current evidence grade Ib. Further controlled clinical trials were recommended. Overall response rates, defined a \> 50 % reduction in pain frequency or VAS scores were higher than 60 % \[[@CR38]\].

Methods and design {#Sec5}
==================

Study design/general structure {#Sec6}
------------------------------

The study design is prospective, randomized, placebo-controlled and double blind (Table [1](#Tab1){ref-type="table"}). A randomized withdrawal design was chosen, which means that all patients who respond positively to the first treatment intervention will consecutively be randomized to continuing the intervention or receiving placebo. This study design is useful in clinical trials with only a small number of patients in order to achieve the necessary statistical power. Since all patients will at least once receive *verum* injections a lower dropout rate can be expected as compared to a study in parallel group design.

The study consists of three phases: baseline phase, single blind phase and double blind phase. Study duration for a single patient will be, depending on therapy response, between 5 and 25 weeks.

During the baseline phase (week −1) TN attack frequency and pain intensity scores (numeric rating scale, NRS) will be assessed with a specific diary. Patients are required to keep their concomitant TN medication (see also "concomitant medication") unchanged. Patients with an average frequency of more than three daily paroxysms will enter the open-label phase of the trial.

Estimated timeline {#Sec7}
------------------

Recruitment will begin in November 2014 and will end in July 2016.

Intervention {#Sec8}
------------

During the single blind phase (weeks 1--12) all eligible patients will receive BT-A injections in accordance to the injection scheme given below. After week 4 non-responders to treatment will finish the study early. Frequency reduction of less than 30 % as compared to baseline phase will be considered a non-response to BT-A.

Double blind phase (weeks 13--24): therapy responders will be randomized to BT-A injections or placebo injection (saline) at the same injection sites. Allocation to the *verum*/placebo arm is double blind: the BT-A will be dissolved in saline in a 0.5 ml/1 ml syringe and 5 U will be injected near to the nerve exits of the affected trigeminal branches (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Fig. 1Flow chart of Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN)Fig. 2Injection scheme of Botulinum neurotoxin type A in the treatment of classical Trigeminal Neuralgia (BoTN). Nerve exits of the affected trigeminal branches will be palpated and identified. Five units of BT-A are injected at three sites per branch 1.5 cm apart. Injection sites of the first trigeminal branch are kept 1.5 cm above the eyebrows in order to prevent ptosis

Primary outcome parameter {#Sec9}
-------------------------

Primary outcome parameter is the average number of TN attacks within the fourth week after double blind intervention in V2.

Secondary outcome parameters {#Sec10}
----------------------------

Change in average TN attack frequency in the fourth week after BT-A/placebo injection in V2 (= week 16) as compared to the last 7 days before V0 and V2.Change in average TN attack frequency in the 2nd, 6th, 8th and 12th weeks after V2 as compared to the last 7 days before V0 and V2.Average pain intensity scores (measured on an 11-point NRS) in the 2nd, 4th, 6th, 8th and 12th weeks after V2 as compared to the last 7 days before V0 and V2.Total number of TN attacks in comparison to baseline and V1.Tolerability and safety: adverse events, abnormal neurological and clinical findings assessed in V1--4, Clinical Global Impression (CGI) assessed in V1--4 \[[@CR39]\].Rescue analgesic medication needed as compared to placebo and run-in phase.Number of days with TN attacks after V2.Therapy response (reduction of TN attacks per day ≥ 30 %) in 4th, 8th and 12th therapy weeks as compared to baseline and in 16th, 20th and 24th weeks as compared to baseline and 12th therapy weekQuality of life/impairment in everyday life assessed in V0, V2 and V4 by a) 12-item short form questionnaire (SF-12), b) Headache Impact Test (HIT-6), c) Allgemeine Depressionsskala: General Depression Scale (ADS) \[[@CR40]--[@CR42]\]

Concomitant drug therapy {#Sec11}
------------------------

### Prophylactic therapy {#Sec12}

Medical prophylactic therapy of TN can be administered as long as dosages remain consistent from 4 weeks prior to the beginning and throughout the course of the study.

The following drugs are permitted, with the respective maximum dosages and under the surveillance of potential side effects: CBZ, OXC, baclofen, phenytoin, gabapentin, lamotrigine, levetiracetam, pregabalin, topiramate und valproic acid.

Opioids and tricyclic antidepressants (e.g. amitriptyline) can potentially alter TN attack frequency and are, therefore, only permitted when the dosage remains unchanged from 4 weeks prior to the beginning of the study and throughout the course of the study.

### Rescue pain medication {#Sec13}

The following analgesic substances and their maximal daily doses are permitted throughout the course of the study, their use should be documented in the patient's diary.Ibuprofen max. 800 mg/dAcetylsalicylic acid max. 1000 mg/dIndomethacin max. 50 mg/dDiclofenac max. 50 mg/dNaproxen max. 250 mg/dParacetamol max. 1000 mg/dMetamizol max. 2000 mg/dMixed analgesics, i.e. Thomapyrin (acetylsalicylic acid 250 mg, paracetamol 200 mg and caffeine 50 mg) 2 tablets per day.

Visit scheme {#Sec14}
------------

### Screening visit ("visit −1") {#Sec15}

In the screening visit a standardized interview is performed: eligibility is assessed and informed consent obtained. Subjective burden will be evaluated with three standardized questionnaires addressing quality of life (SF-12), depression (ADS) and headache severity headache (HIT-6).

Medical and neurological examinations are performed and blood samples are obtained in order to screen for acute infections and disorders of hemostasis. A pain diary is handed out for the assessment of the patient\`s baseline TN attack frequency.

### Visit 0 (baseline) {#Sec16}

This visit is scheduled 8 days after the screening visit. Eligible study patients with an average of three or more TN paroxysms per day during baseline phase are treated with BT-A injections in a single blinded manner (for further details see "blinding process" below).

### Visit 1 {#Sec17}

Visit 1 is performed between 28 and 31 days after V0 and consists of a standardized, interview as well as medical and neurological examination. ADS, HIT-6 and SF-12 scores are reassessed and adverse events documented. Patients with insufficient therapy response finish the study early.

### Visit 2 {#Sec18}

Visit 2 (between 84 and 87 days after V0) consists of the second, this time double blind, placebo controlled, intervention and in addition to that neurological and medical examination and assessment of adverse events and ADS, HIT-6 and SF-12 scores.

### Visit 3 {#Sec19}

V3 is comparable to V1 and is scheduled 28--31 days after V2. A standardized interview, medical and neurological examination, assessment of ADS, HIT-6 and SF-12 scores as well as documentation of all adverse events are performed.

### Visit 4 {#Sec20}

V4 (between 84 and 87 days after V2) is the final visit and includes neurological and medical examination and assessment of adverse events (including lab work) and ADS, HIT-6 and SF-12 scores. Responders to BT-A therapy are offered continuing BT-A injections as off-label-treatment, if health care providers offer reimbursement of the therapy costs.

Laboratory testing {#Sec21}
------------------

Laboratory testing will be performed in V1 including: alanine transaminase, aspartate transaminase, gamma-glutamyl transpeptidase, hemoglobin, white blood cell count, platelet count, creatinine, c-reactive peptide, prothrombin time/international normalized ratio (INR), and partial thromboplastin time.

Additional neurophysiological testing {#Sec22}
-------------------------------------

The analgesic mechanisms of BT-A on the trigeminal nociceptive system will be further examined by neurophysiological tests: before visits V0--V4 nociceptive blink reflex and pain-related evoked potentials will be recorded using a concentric electrode which generates a series of short painful stimuli over nerve branch V1 of the affected side. This method is established in the testing of trigeminal nociceptive fiber function and the evaluation of supraspinal trigeminal pain processing and central facilitation. It has been used in studies of TN as well as other headache disorders and has no known serious side effects \[[@CR43]--[@CR46]\]. For more information on recording technique, background information and informative value please see reference \[[@CR47], [@CR48]\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Nociceptive blink reflex and pain- related evoked potentials

Randomization/blinding process {#Sec23}
------------------------------

Before participation in the trial patients are informed that in the two scheduled interventions they will receive at least once a *verum* injection with BT-A.

The first intervention in V1 is single blind: BT-A is dissolved in 0.9 % saline and filled in 1- ml injection syringes. This process is not visible to the patient.

The second intervention in V2 is double blind and, therefore, the process of reconstitution will be performed in the pharmacy of the University Hospital Essen:Prior to the intervention (\<24 hours) a pharmacist, who is not further involved in the conduction and/or analysis of the study dissolves either BT-A in 1 ml of 0.9 % saline or fills the 1-ml injection syringes solely with 0.9 % saline. This process is not visible either to the patient or to any member of the study groupThe allocation to the *verum* or placebo group is done in a pseudorandomized manner: a randomization list assigns screening numbers of patients to either the placebo or *verum* group. This list is only accessible to the pharmacist who is responsible for the reconstitution of BT-A. The screening number is handed out to the pharmacy prior to the intervention by a member of the study group.

Eligibility {#Sec24}
-----------

### Inclusion criteria {#Sec25}

Men and women age 18 years or more, of legal competence and with sufficient knowledge of written and spoken German, capable of presenting themselves to regular visitsDiagnosis of classic TN as defined in the International Classification of Headache Disorders, third edition (ICHD-3 beta)Baseline TN frequency of at least 3 paroxysms per day for \< 15 days/monthAt least 1 treatment attempt with CBZ and either insufficient therapy response under a daily dosage of at least 600 mg/d or intolerable side effectsStable dosage of concomitant TN drug therapy in the last 4 weeks before participation in the studyStable dosage of concomitant drug therapy with potential influence on TN frequency and pain intensity (tricyclic antidepressants, opioids).

### Exclusion criteria {#Sec26}

Symptomatic painful trigeminopathies/symptomatic TNHistory of trigeminoautonomic headache syndromes:Short-lasting Unilateral Neuralgiform headache with Conjunctival injection and Tearing (SUNCT)Short-lasting Unilateral Neuralgiform headache with conjunctival injection and Autonomic features (SUNA)Paroxysmal hemicraniaCluster headacheKnown sensitivity/intolerance to BT-AContraindications against Botox® according to summary of product characteristics: [www.allergan.com](http://www.allergan.com)Local inflammation at injection siteImpaired hemostasis, anticoagulatory medicationKnown motor neuron or neuropathic diseaseImpairment of neuromuscular transmissionHistory of dysphagiaCorneal ulcerationSevere allergic diathesisTerminal or psychiatric comorbiditiesPregnancyNursing periodHistory of alcoholism/substance abuse

Excluded therapies and medications {#Sec27}
----------------------------------

Concomitant medication/non-medical treatment will be documented. The following substances which can potentially alter the efficacy of BT-A cannot be taken during the study and need to be stopped at least 10 days prior to the beginning of the study:SpectinomycinAminoglycosidesSubstances blocking neuromuscular transmission, e.g. non-depolarizing muscle relaxants, succinylcholine, dantrolene

Anticoagulatory drugs cannot be taken during the study and need to be stopped at least 10 days prior to the beginning of the study:Oral anticoagulants (dabigatran, rivaroxaban, abixaban, coumarin-derivatives)Heparin and low molecular weight heparins in effective anticoagulatory dosage

Assessment of representativeness {#Sec28}
--------------------------------

All patients screened for BoTN will be registered and documented (date, age, sex, reason for exclusion) in order to assess representativeness of the included patient group.

Patients can always withdraw their consent to participate in the study without stating a reason.

Statistical analysis and sample size considerations {#Sec29}
---------------------------------------------------

### Definition of study populations {#Sec30}

Safety assessment group {#Sec31}
-----------------------

Every patient who received BT-A at least once will be included in the safety assessment group. Patients who quit the study early should still participate in the following visits for safety assessment.

ITT population {#Sec32}
--------------

The intention-to-treat-analysis (ITT) population will consist of patients who have received study medication once, but analyses will be performed with respect to randomization allocation.

Randomized ITT population {#Sec33}
-------------------------

All responders in the first single blinded part of the trial will be included in the analysis of the randomized ITT population.

PP population {#Sec34}
-------------

The per-protocol (PP) population excludes patients with protocol violations such as violation of inclusion/exclusion criteria or illegitimate changes in concomitant medication. Prior to unblinding the sponsor and the responsible biometrician will determine whether the patient will be allocated to PP-analysis or ITT-analysis.

### Efficacy {#Sec35}

The primary endpoint in the efficacy assessment is the average number of TN paroxysms within the fourth week after double blind intervention in V2 (the last 4 days before V3). The confirmatory analysis of the primary endpoint will be the comparison of the *verum* (μ~Botox~) and placebo group (μ~placebo~) with the following, formal hypotheses:$$\documentclass[12pt]{minimal}
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The confirmatory testing will be performed with the randomized ITT population.

### Sensitivity analysis {#Sec36}

Due to the small sample size further subgroup analysis will be limited to separate assessment of the female and male patient population.

Secondary endpoints will undergo explorative and descriptive analysis -- e.g. in the ITT and PP populations. Details will be described in a statistical analysis plan.

### Safety {#Sec37}

All patients of the safety assessment group will take part in the analysis of tolerability and safety. The assessment is part of the screening and all follow-up visits and contains: medical and neurological examination and grading of tolerability on a four-point scale. Adverse events and suspected adverse effects will be separately documented in the Case Report Form (CRF) including duration, severity, their possible relation to the study medication, medical measures taken and its outcome. Severe adverse events will be published as single case reports.

### Sample size and power {#Sec38}

Primary endpoint is the average number of TN paroxysms within the fourth week after double blind intervention. The effect size is estimated at 1.2 and the sample size is calculated by using the Wilcoxon-Mann-Whitney test (software used is G® Power Version 3.1.9.2.).

With *α* = 0.05 and *β*-error = 0.80 the expected sample size per group is *n* = 14, respectively n = 17 considering the expected drop-out rate of 20 %.

Overall a total of 34 recruited patients is expected to be necessary and at least 28 patients need to enter the randomized double blind arm of the trial. Further patients will be recruited if there are more non-responders to treatment as estimated.

### Quality assurance/monitoring {#Sec39}

Due to the small size of this study the sponsor disclaims external monitoring. The sponsor is held responsible for the surveillance of this study and monitoring activity (e.g. source data verification, assessment of protocol violations) will be performed by a person (monitor) with the adequate qualification who is not further involved in the execution and analysis of this trial. All patients will be monitored.

Every member of the study group has received the necessary training in the conduction of this specific trial and is adequately qualified in accordance with Good Clinical Practice (GCP).

Informed consent, ethics, data safety monitoring board {#Sec40}
------------------------------------------------------

### Informed consent {#Sec41}

A written informed consent must be obtained from all patients before the trial. This will also be documented in the clinical file. Informed consent includes general characteristics of the study, alternative treatment options, potential risks and benefits from the study, as well as the right to withdraw consent at any given time.

### Ethics/legal approval {#Sec42}

All procedures of this study are in accordance to the German legal regulations of the Medicinal Products Act (AMG), the Declaration of Helsinki and the current version of the International Conference on Harmonization-GCP (ICH-GCP) guidelines. The conduct of this trial, as well as its study protocol have been approved by the responsible ethics committee of the university of Duisburg-Essen, as well as by the responsible surveilling authorities Bundesinstitut für Arzneimittel und Medizinprodukte, the Federal Institute for Drugs and Medical Devices (BfARM).

### List of the responsible ethics committees {#Sec43}

The Ethics Committee of the Medical Faculty of the University of Duisburg-Essen, see also Additional file [1](#MOESM1){ref-type="media"} ("List of the responsible ethics committee and surveilling authorities") for further details.

Discussion {#Sec44}
==========

BoTN investigates the efficacy and safety of local BT-A injections in the treatment of otherwise therapy-refractory TN in addition to concomitant standard drug treatment. All eligible patients will be first treated with *verum* in a single blinded manner. Responders will be randomized 1:1 to a second intervention that is double blind, placebo controlled (randomized withdrawal design).

Local BT-A injections may prove to be a potentially safe and efficient additional treatment option for severe cases of TN. Additional neurophysiological testing may provide further insight into the antinociceptive mechanisms of BT-A.

Trial status {#Sec45}
------------

Patient recruitment has begun and is still ongoing.

Consent {#Sec46}
-------

Written informed consent was obtained from the patient(s) for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the editor-in-chief of this journal.

Additional file {#Sec47}
===============

Additional file 1:**List of the responsible ethics committee and surveilling authority.** List includes name and address of the responsible ethics committee and the responsible federal surveilling authority. (DOCX 15 kb)

ADS

:   Allgemeine Depressionsskala: General Depression Scale -- a psychometric self-assessment screening test for depression

AMG

:   German legal regulations of the Medicinal Products Act

BfARM

:   Bundesinstitut für Arzneimittel und Medizinprodukte, Federal Institute for Drugs and Medical Devices

BMBF

:   German Ministry of Education and Research

BT-A

:   botulinum toxin type A

CBZ

:   carbamazepine

CGI

:   Clinical Global Impression -- a scale that helps evaluating effects of therapeutic intervention, regarding severity of disease, improvement efficacy and adverse effects of therapy

CRF

:   Case Report Form

GCP

:   Good Clinical Practice

HIT-6

:   Headache Impact Test-6 -- a 6-item questionnaire for screening and monitoring outcomes of patients with headache

ICH

:   International Conference on Harmonization

INR

:   international normalized ratio

ITT

:   intention-to-treat, NRS, numeric rating scale

OXC

:   oxcarbazepine

PP

:   per-protocol

RCT

:   randomized controlled trial

SF-12

:   12-item short form questionnaire: a questionnaire to assess quality of life

SUNA

:   Short-lasting Unilateral Neuralgiform headache with conjunctival injection and Autonomic features

SUNCT

:   Short-lasting Unilateral Neuralgiform headache with Conjunctival injection and Tearing

TN

:   trigeminal neuralgia

VAS

:   visual analogue scale

ZKSE

:   Zentrum für Klinische Studien Essen: Center for Clinical Trials Essen
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Study site {#FPar1}
==========

Universitätsklinikum Essen, Klinik und Poliklinik für Neurologie, Hufelandstr. 55, 45122 Essen, Germany; Principal Investigator: PD Dr. M. Obermann.
